Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debby Van Dam

Showing results (11-20 of 117) with videos related to

Pageof 12
Sort By:
Psychopharmacology|January 18, 2005
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 modelDebby Van Dam, Dorothee Abramowski, Matthias Staufenbiel, et al.
International Journal of Alzheimer'S Disease|June 11, 2011
Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's DiseasePeter Wostyn, Debby Van Dam, Kurt Audenaert, et al.
Journal of Neurochemistry|March 27, 2025
Monoaminergic Alterations at the Subregional Cervical and Thoracic Spinal Cord Level of Patients Within the FTD-ALS Continuum and Early-Onset AD: Low Thoracic Dopaminergic Activity in ALSAnnelies Heylen, Yannick Vermeiren, Peter Paul De Deyn, et al.
Journal of Chromatography. A|May 27, 2014
Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissueDebby Van Dam, Yannick Vermeiren, Tony Aerts, et al.
Arzneimittel-Forschung|August 6, 2008
Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviourEllen Vloeberghs, Katrien Coen, Debby Van Dam, et al.
Frontiers in Neuroscience|April 5, 2018
Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar OutcomesYannick Vermeiren, Jana Janssens, Debby Van Dam, et al.
Methodsx|July 8, 2015
Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment methodLeen Janssen, Frank Sobott, Peter P De Deyn, et al.
Journal of Neurogenetics|October 26, 2011
Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesisPeter Wostyn, Debby van Dam, Kurt Audenaert, et al.
Neuroscience|December 1, 2019
Pentylenetetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of TauopathyJan Van Erum, Femke Valkenburg, Debby Van Dam, et al.
Current Alzheimer Research|May 1, 2013
Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunitiesDebby Van Dam, Annemie Van Dijck, Leen Janssen, et al.
Pageof 12

Showing results (11-20 of 117) with videos related to

Sort By:
Pageof 12
Psychopharmacology|January 18, 2005
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 modelDebby Van Dam, Dorothee Abramowski, Matthias Staufenbiel, et al.
International Journal of Alzheimer'S Disease|June 11, 2011
Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's DiseasePeter Wostyn, Debby Van Dam, Kurt Audenaert, et al.
Journal of Neurochemistry|March 27, 2025
Monoaminergic Alterations at the Subregional Cervical and Thoracic Spinal Cord Level of Patients Within the FTD-ALS Continuum and Early-Onset AD: Low Thoracic Dopaminergic Activity in ALSAnnelies Heylen, Yannick Vermeiren, Peter Paul De Deyn, et al.
Journal of Chromatography. A|May 27, 2014
Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissueDebby Van Dam, Yannick Vermeiren, Tony Aerts, et al.
Arzneimittel-Forschung|August 6, 2008
Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviourEllen Vloeberghs, Katrien Coen, Debby Van Dam, et al.
Frontiers in Neuroscience|April 5, 2018
Serotonergic Dysfunction in Amyotrophic Lateral Sclerosis and Parkinson's Disease: Similar Mechanisms, Dissimilar OutcomesYannick Vermeiren, Jana Janssens, Debby Van Dam, et al.
Methodsx|July 8, 2015
Signal loss due to oligomerization in ELISA analysis of amyloid-beta can be recovered by a novel sample pre-treatment methodLeen Janssen, Frank Sobott, Peter P De Deyn, et al.
Journal of Neurogenetics|October 26, 2011
Genes involved in cerebrospinal fluid production as candidate genes for late-onset Alzheimer's disease: a hypothesisPeter Wostyn, Debby van Dam, Kurt Audenaert, et al.
Neuroscience|December 1, 2019
Pentylenetetrazole-induced Seizure Susceptibility in the Tau58/4 Transgenic Mouse Model of TauopathyJan Van Erum, Femke Valkenburg, Debby Van Dam, et al.
Current Alzheimer Research|May 1, 2013
Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunitiesDebby Van Dam, Annemie Van Dijck, Leen Janssen, et al.
Pageof 12